Editas Medicine
EDIT
235 hedge funds and large institutions have $263M invested in Editas Medicine in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 65 increasing their positions, 72 reducing their positions, and 37 closing their positions.
43% more call options, than puts
Call options by funds: $2.6M | Put options by funds: $1.83M
32% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 37
4% more funds holding
Funds holding: 225 → 235 (+10)
10% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 72
14.47% less ownership
Funds ownership: 83.04% → 68.57% (-14%)
48% less capital invested
Capital invested by funds: $504M → $263M (-$240M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$4.61M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.6M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$2.67M |
| 4 |
HF
HRT Financial
New York
|
+$1.68M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$23.5M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$7.76M |
| 3 |
Morgan Stanley
New York
|
-$4.88M |
| 4 |
Two Sigma Investments
New York
|
-$4.78M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$4.71M |
EDIT Hedge Fund Activity: Q2 2024 in Review
235 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2024, worth a combined $263M — down 48% from $504M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new EDIT positions and 37 closed out — a net gain of 12 holders — while 65 added to existing stakes and 72 trimmed.
The largest buyer was UBS AM, adding an estimated $4.61M. The largest seller was State Street, cutting an estimated $23.5M.
- 235 institutional investors held Editas Medicine (EDIT) as of Q2 2024, up from 225 in Q1 2024.
- Funds reported $263M of Editas Medicine stock for Q2 2024, down 48% quarter-over-quarter.
- 49 funds opened new Editas Medicine positions in Q2 2024 and 37 closed out, a net change of +12 holders.
- The largest Editas Medicine buyer in Q2 2024 was UBS AM, an estimated $4.61M added.
- The largest Editas Medicine seller in Q2 2024 was State Street, an estimated $23.5M sold.
Based on aggregated 13F filings for Q2 2024.